News summary produced by Claude AI
The U.S. Department of Defense announced a new policy requiring testosterone deficiency screenings during annual physical examinations for service members once they reach 30 years of age. Defense Secretary Pete Hegseth made the announcement on Wednesday as part of broader efforts by the Trump administration to promote testosterone replacement therapy and position the hormone as integral to health and masculinity.
The policy reflects a wider trend in which testosterone replacement therapy has gained prominence through health influencers and online clinics marketing the treatment beyond what current medical evidence supports. Medical experts have raised concerns about the scope and benefits attributed to such therapies in recent public discourse.
The announcement has drawn attention to a stark contradiction in how testosterone access is being treated across different populations. While the military initiative frames testosterone as essential to service member readiness, the same administration has worked to restrict transgender individuals’ access to testosterone and other hormone medications. Transgender people, many of whom rely on testosterone as part of medically necessary treatment, were banned from military service the previous year. The policy raises questions about differential access to the same medication based on population and identity.
Medical professionals and advocates have questioned the reasoning behind promoting testosterone replacement therapy as universal preventive care for military personnel while simultaneously limiting access for other groups, particularly given that testosterone is chemically identical regardless of the patient’s identity or medical context.